

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 5, 2014

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33609

30-0520478

(State or Other Juris-
diction of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

4520 East-West Highway, 3rd Floor
Bethesda, Maryland

20814

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure.

On June 5, 2014, Sucampo Pharmaceuticals, Inc. ("Company") will make corporate update presentations via webcast at an investor conference in New York, NY at the Jefferies 2014 Global Healthcare Conference. All meetings will include the slides filed on Form 8-K dated May 19, 2014 including modifications to 8 slides. The modified slides are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 The modifications of the 8 slides to the corporate update presentation slides dated June 5, 2014.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: June 5, 2014

By: /s/ Thomas J. Knapp

Name: Thomas J. Knapp
Title: EVP, Chief Legal Officer and
Corporate Secretary

At-A-Glance: Sucampo Pipeline

CLINICAL FOCUS LEAD COMPOUNDS	STAGE OF CLINICAL DEVELOPMENT			
	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Lubiprostone Pediatric Functional Constipation				Began Q4 13
Lubiprostone Alternate Formulation CIC				Began Q3 13
Unoprostone Isopropyl Retinitis Pigmentosa*				Began Q1 13
Cobiprostone Oral Mucositis			P2a 2H 14	
IV Ion Channel Activator Lumbar Spinal Stenosis			P2a 2H 14	
PO Ion Channel Activator Lumbar Spinal Stenosis		P1b Began Q1 14		

■ COMPLETED ■ PROJECTED START ■ ONGOING

*Co-developing with R-Tech Ueno, Ltd.

Lubiprostone Clinical Development

Pediatric Functional Constipation (PFC)

- Prevalence: \approx 4 - 37% of children worldwide have functional constipation⁴
- Initiated global pivotal P3 clinical program for lubiprostone for children and adolescents aged 6 - 17 years with PFC
 - First patients enrolled into follow-on, safety extension study in April 2014
 - Takeda is funding 70% of development costs



Abdominal radiograph of constipated child showing stool throughout the colon

Liquid Formulation

- Based on FDA input and trial results, looking at alternative formulation
 - Takeda funding 100% of the costs, including additional formulation work

Unoprostone Isopropyl for Retinal Disease

Retinitis Pigmentosa (RP)

- Prevalence: ≈ 1 in 4,000 individuals⁶ WW suffer from RP
- Degenerative retinal disease with no approved prescription medicines available⁶
- Ongoing P3 clinical trial by development partner, R-Tech Ueno, Ltd.
 - Interim 1 yr results available early 2015
- Unoprostone isopropyl has orphan drug designation for RP in U.S. & E.U.
 - Sucampo will work with regulatory authorities in U.S. & E.U. to determine required incremental data for filing in each region



See Reference 6, 7 (Photo)

Key Facts, Financial Highlights & Guidance

Key Facts	
Trading Symbol	SCMP (NASDAQ)
Corporate Headquarters	Bethesda, MD
Stock Price (05-30-14), 52-Week Range	\$7.27; \$11.00 to \$5.40
Shares Outstanding (05-30-14)	44.5M (1 class of common stock)
Daily Volume (90-day average)	212,533
Market Capitalization (05-30-14)	\$323.2M
Enterprise Value (05-30-14)	\$270.4M
Financial Highlights for Q1 2014	
Cash & Equivalents	\$106.0M
Total Revenue	\$22.2M
Net Income	\$0.7M
EPS	\$0.02
AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes):	\$75.0M
Financial Guidance	
2014 Guidance – Net Income	\$3M - \$5M, or \$0.06 - \$0.11 (EPS)

Upcoming Events

2H 2014

Commercial

AMITIZA OIC indication potential approval in Switzerland

AMITIZA NICE potential endorsement in the U.K.

Clinical

Beginning phase 2a trial of cobiprostone in oral mucositis

Beginning phase 2a trial of IV Ion Channel Activator Lumbar Spinal Stenosis

Conclusion in Q3 2014 of phase 1b trial of orally administered ion-channel activator for lumbar spinal stenosis

Financial

Q2 2014 Earnings call August 2014

Corporate

Corporate Strategy Update Q3 2014

Key Facts & Financial Highlights

Key Facts	
Trading Symbol	SCMP (NASDAQ)
Corporate Headquarters	Bethesda, MD
Stock Price (05-30-14), 52-Week Range	\$7.27, \$11.00 to \$5.40
Shares Outstanding (05-30-14)	44.5M (1 class of common stock)
Daily Volume (90-day average)	212,533
Market Capitalization (05-30-14)	\$323.2M
Enterprise Value (05-30-14)	\$270.4M

Financial Highlights for Q1 2014	
Debt	\$52.2M
Cash & Equivalents	\$106.0M
Total Operating Expense	\$16.0M
Total Revenue	\$22.2M
Net Income	\$0.7M
R&D Revenue	\$1.8M
Product Royalty Revenue	\$13.5M
R&D Expense	\$5.1M
EPS	\$0.02
AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes):	\$75.0M

Sucampo Prostone Pipeline Key Highlights

Cobiprostone for Oral Mucositis

Oral Mucositis


- Incidence ≈123,000 HNC patients in the U.S. per year¹⁴
- Formation of ulcers that result from radiation therapy and chemotherapy in cancer patients
 - Total WW market estimated to be up to \$500M⁴
 - Also impacts patients treated for solid tumors, or receiving hematopoietic stem cell transplantation
- Completed a P1b trial of cobiprostone evaluating its safety and pharmacokinetics
 - Well-tolerated and low systemic exposure
- Expect to begin a P2a trial of cobiprostone in 2H 2014



Ion Channel Activators for Lumbar Spinal Stenosis

Lumbar Spinal Stenosis (LSS)

- Prevalence: ≈400,000 Americans, most >60 years of age⁸
- Degenerative change in lumbar spine; unmet medical need with limited treatment options globally⁴
- Top-line results of P2a, double-blind, placebo-controlled trial of IV ion channel activator showed statistically significant improvement in VAS* pain



- Initiated P1b evaluating safety and PK of orally administered ion channel activator; conclude Q3 2014
- Currently assessing our next steps for both oral and IV ion channel activators; will update conclusions in Q3 2014

See References 8;9;11;12, References 10; 13 (Photo)

References

1. IMS Smart View, NPA Report, client Factored Numbers
2. Internal Research
3. Fingertip Formulary (NOV 2013)
4. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. *Am J Gastroenterol*. 2011 May;106(5):835-42
5. Radiograph from Borowitz - [Pediatric Constipation article](#) on Medscape website; accessed 09.19.13
6. Sucampo data on file
7. Photos from Foundation Fighting Blindness website [What is Retinitis Pigmentosa?](#); accessed 09.19.13
8. Based on statistics from the American Cancer Society and the National Cancer Institute
9. Trotti A *et al*. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. *Radiother Oncol*. 2003 Mar;66(3):253-62
10. Photos from Silverman - Diagnosis and management of oral mucositis. *J Support Oncol* 2007; 5 (2 Suppl 1):13-21
11. Clearview Analysis 2008
12. The American Association of Neurological Surgeons website [Lumbar Spinal Stenosis](#); accessed 09.19.13
13. Diagram from American Academy of Orthopaedic Surgeons website [Lumbar Spinal Stenosis](#); accessed 09.19.13
14. National Cancer Institute SEER Database (2012)